BD&L strategy for oncology leadership

Less than 1 min read

Resource, Commercial, Portfolio, Licensing & Development

Over the last decade, oncology revenue growth for top pharma players has largely been driven by BD&L. Our experts take a deep dive into the growing oncology market uncovering the top drivers and activities of revenue growth.

Explore the full analysis, takeaways, and strategic recommendations for how to engage in BD&L to drive growth in oncology.

Read the full analysis

Contact us.

To speak with our experts, fill out the form below.

Insights

More insights.

See all insights

Ruth Zeidman

The expanding concept of value – Implications for manufacturers and payers

Micro-tutorial on payer value drivers, tackling challenges in their integration into payer/HTA frameworks and generating robust supporting evidence.

Preparing for ASH 2023: Heme-oncology research & abstracts

We’re sharing some spotlights to help support our clients and partners navigate ASH 2023.

Spotlight on antibody drug conjugates (ADCs)

ADCs continued to be a spotlight at ESMO 2023. The team shares its key value drivers and associated limitations.

Centers of Excellence

AI at Putnam

Open roles